- GlycoMimetics (NASDAQ:GLYC) is up 24% premarket on modestly higher volume on the heels of its announcement of positive results from a Phase 1/2 clinical trial assessing GMI-1271 in patients with relapsed/refractory acute myeloid leukemia (AML) and in older patients with newly diagnosed AML. Ther data were presented at ASH in Atlanta.
- In 54 patients with relapsed/refractory AML who received the Phase 2 dose (median follow-up of 6.6 months), the clinical remission rate was 43% (n=23/54). Median overall survival (OS) was 9.4 months while median duration of remission was 11.1 months.
- In 25 older patients with newly diagnosed AML (median follow-up of 10.5 months), the clinical remission rate was 68% (n=17/25). Median OS was 15.8 months while median duration of remission was 14.8 months. Median event-free survival was 11.3 months.
- GMI-1271 was generally well-tolerated. There was a 3% rate of severe, debilitating oral mucositis, well below the historical rate of 20 - 25%.
- A Phase 3 study should commence in mid-2018.
- GMI-1271 is an E-selectin antagonist which disrupts known pathways of tumor resistance which improves the effectiveness of chemotherapy.
- Now read: Selectin Inhibition Justifies GlycoMimetics Investment
Original article